Use of metformin for women with polycystic ovary syndrome

Human Reproduction Update

Volumn 19, Issue 1, 2013, Pages 1-

  Tang, Thomas ^a   Balen, Adam H ^b  

^a ROYAL MATERNITY HOSPITAL   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; METFORMIN;

ABDOMINAL OBESITY; BIRTH RATE; COMBINATION CHEMOTHERAPY; HUMAN; LETTER; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; TREATMENT OUTCOME;

DRUG UTILIZATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME;

EID: 84870365278     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dms040     Document Type: Letter

References (1)

1. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, Dchiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012. Issue 5. Art. No.: CD003053. doi:10.1002/14651858.CD003053.pub5.